ABSTRACT
Attention and executive function difficulties are common in many neurodevelopmental conditions and significantly impact psychological well-being. However, access to cognitive assessment remains limited due to high costs and resource constraints. To address this gap, the Stap2Go test was developed as a digital, cost-effective, and accessible screening tool for assessing attention and executive functions. This study examined the convergent validity of Stap2Go by comparing it with the CPT3. It also evaluated the sensitivity and specificity of Stap2Go in detecting altered scores by comparing children with ADHD (both medicated and unmedicated) to children without ADHD. Additionally, it explored whether medication may mask attentional difficulties, emphasizing the importance of conducting assessments off-medication. The sample included 52 children with ADHD and 49 typically developing children. Moderate correlations were found between Stap2Go and CPT3. Stap2Go demonstrated good sensitivity in detecting altered scores in children with ADHD and high specificity in the control group.